Drugmakers tumble on reports FDA's top vaccine regulator set to leave [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
top vaccine official had been forced to resign, the most high-profile exit at the regulator amid an overhaul of federal agencies. Shares of vaccine-focused Moderna slumped 12.4% to $27.25 in premarket trading, while those of Pfizer declined 1.8%. Gene therapy-focused companies such as Taysha Gene Therapies, Solid Biosciences and Sarepta Therapeutics fell between 4% and 10%. Peter Marks, who played a key role in President Donald Trump's first term in developing COVID-19 vaccines, will leave effective April 5, the Wall Street Journal and other media outlets reported on Friday. As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited the development of rare disease treatments and gene therapies during his tenure. Marks' departure follows the exit of head of the FDA's drug evaluation unit, Patrizia Cavazzoni, roughly two months ago. It also comes as U.S. Secretary of Health and Human Services Robert F. Kennedy
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TSHA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..MarketBeat
TSHA
Earnings
- 11/4/25 - In-Line
TSHA
Sec Filings
- 12/1/25 - Form 4
- 11/28/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TSHA's page on the SEC website